# Gout

Manage gout by confirming or strongly supporting monosodium urate deposition, excluding septic arthritis in an acutely inflamed joint, selecting flare therapy by comorbidity, and using treat-to-target urate lowering with prophylaxis to dissolve deposits and prevent recurrent disease.

**Clinical question:** How should physicians diagnose gout, treat acute flares, and implement urate-lowering therapy while minimizing treatment-related flares?

Updated: 2026-08-24T16:15:29.758172+00:00

## What matters in practice
- Identify monosodium urate crystals in synovial fluid or tophus aspirate whenever feasible; this is sufficient to classify gout and remains the diagnostic reference standard. [2][21]
- An acutely inflamed joint still requires exclusion of septic arthritis before attributing symptoms to gout, particularly when corticosteroids are being considered. [5]
- For an acute flare, select colchicine, an NSAID, or glucocorticoids according to contraindications, comorbidity, prior response, and joint distribution. [23][18]
- Use allopurinol as first-line urate-lowering therapy, start at a low dose, titrate gradually, and monitor serum urate and renal function to achieve serum urate below 6 mg/dL. [7][10][14]
- When starting urate-lowering therapy, prescribe flare prophylaxis with low-dose colchicine or low-dose NSAID therapy; colchicine 0.5 mg once or twice daily or naproxen 250 mg twice daily are described options for up to 6 months. [12][22]
- Reserve pegloticase for uncontrolled gout meeting labeling-type features such as serum urate at least 7 mg/dL with inability to maintain urate below 6 mg/dL on other urate-lowering therapy, intolerance to therapy, and/or clinically evident tophi. [1]

## Confirm urate deposition and do not miss septic arthritis

Treat a hot swollen joint as a diagnostic problem before treating it as uncomplicated gout.

Aspiration of a symptomatic joint or bursa for polarized-light microscopy is the preferred confirmatory test when the diagnosis is uncertain, the presentation is atypical, or infection is plausible. Detection of monosodium urate (MSU) crystals in synovial fluid or a tophus is sufficient for gout classification. A negative aspirate lowers, but does not eliminate, classification probability; the 2015 criteria assign negative points when trained microscopy does not identify MSU crystals. [2][21]

Exclude septic arthritis before using corticosteroids in a presumed crystal flare. This is especially consequential in chronic kidney disease, where NSAID avoidance and diabetes-related corticosteroid risk may narrow anti-inflammatory options, but neither circumstance justifies bypassing infection assessment. [5]

If aspiration is unsuccessful or not feasible, use ultrasound for a double-contour sign or dual-energy CT (DECT) for urate deposition as supportive evidence. DECT has good diagnostic accuracy for MSU deposits but lower sensitivity in early disease; do not use a negative early DECT to exclude gout. [2][3][18]
- Use serum urate as a probability modifier, not a stand-alone diagnostic test: serum urate below 4 mg/dL receives negative weight in the ACR/EULAR classification system, whereas a value from 4 to below 6 mg/dL adds no points. [2]
- When crystals are not demonstrated, apply the ACR/EULAR classification framework; a score of at least 8 classifies gout, with reported sensitivity of 92% and specificity of 89%. [2]
- Obtain radiographs when chronic structural disease is suspected; gout-related erosion is an imaging domain in the ACR/EULAR classification criteria. [2]

*Diagnostic evidence that changes the next step in suspected gout. [2][3][18][21]*

| Finding or test | Interpretation | Next action |
| --- | --- | --- |
| MSU crystals in synovial fluid or tophus aspirate | Confirms urate crystal deposition for classification. [2][21] | Treat the flare and assess indication for long-term urate lowering. [2][7] |
| Negative MSU microscopy by trained examiner | Reduces classification probability but does not by itself exclude gout. [2] | Reassess for alternative crystal or infectious arthritis; consider imaging if aspiration is nondiagnostic or infeasible. [2][18] |
| Ultrasound double-contour sign | Supports urate deposition. [2] | Use with clinical findings when aspiration cannot be obtained. [2][18] |
| DECT urate deposition | Supports gout; sensitivity is lower in early disease. [3] | A positive study can support diagnosis; a negative early study should not end evaluation. [3] |
| Concern for septic arthritis | Crystal arthritis and infection must be distinguished before immunosuppressive flare therapy. [5] | Perform joint aspiration and infection-directed evaluation rather than empiric corticosteroid treatment alone. [5] |

## Choose flare therapy by contraindication profile and timing

Treat promptly after evaluating for infection; choice is driven more by safety than by major efficacy differences.

Use colchicine, an NSAID, or glucocorticoids for a gout flare. The ACR guideline includes oral, intra-articular, and intramuscular glucocorticoids among first-line options, and comparative evidence indicates broadly similar flare control among oral colchicine, NSAIDs, and glucocorticoids, with different adverse-effect profiles. [23][18]

For a patient without an NSAID contraindication, naproxen is a practical option. In the CONTACT trial, naproxen produced little difference in pain reduction versus low-dose colchicine but caused fewer adverse effects, less rescue analgesic use, and slightly lower costs; naproxen 500 mg twice daily has also demonstrated equivalence to prednisolone for gout flares. [6]

Use low-dose colchicine early in a flare when clinically appropriate. The AGREE low-dose regimen was 1.8 mg over 2 hours; ACR-cited practice may continue colchicine 0.6 mg once or twice daily until flare resolution. Avoid routine colchicine in severe CKD (G4–G5) under EULAR guidance, although observational evidence suggests cautiously reduced dosing with close monitoring may be possible in selected patients. [6][5]

Use systemic or local glucocorticoids when NSAIDs or colchicine are unsuitable, but first address infection risk. Short courses may have an acceptable risk-benefit profile in CKD, whereas diabetes and infection susceptibility are important tradeoffs. [11][5]
- Avoid NSAIDs when renal risk or other contraindications outweigh benefit; CKD commonly constrains NSAID use during gout flares. [5]
- Review interacting drugs before colchicine: colchicine is influenced by CYP3A4 and P-glycoprotein pathways, and it is contraindicated in renal or hepatic dysfunction when a P-glycoprotein inhibitor is being taken. [5][24]
- Consider an interleukin-1 inhibitor only when standard therapies are unsuitable; IL-1 inhibitors are reported as effective and safe for flares in patients unable to use standard treatments. [16]

*Selection of anti-inflammatory therapy for an acute gout flare. [5][6][18][23][24]*

| Option | Useful setting | Key limitation or action |
| --- | --- | --- |
| Naproxen | Patient without an NSAID contraindication; naproxen 500 mg twice daily has trial evidence comparable with prednisolone. [6] | Avoid when renal risk or other NSAID contraindications are present. [5] |
| Low-dose colchicine | Early flare treatment; AGREE low-dose regimen totaled 1.8 mg over 2 hours. [6] | Avoid in severe CKD under EULAR guidance; check CYP3A4/P-glycoprotein interactions and renal/hepatic function. [5][24] |
| Glucocorticoid | Alternative when NSAIDs or colchicine are unsuitable; oral, intra-articular, and intramuscular routes are guideline-listed. [23] | Exclude septic arthritis; account for diabetes and infection risk. [5] |
| IL-1 inhibitor | Patient unsuitable for standard therapies. [16] | Use as a nonstandard escalation after assessing infection and standard-agent contraindications. [16] |

## Start urate-lowering therapy for recurrent or burdensome disease

Anti-inflammatory therapy controls the current attack; sustained urate reduction addresses crystal burden.

Discuss urate-lowering therapy (ULT) with patients who have recurrent attacks, tophi, urate arthropathy, renal damage, or symptomatic very high serum urate. Shared decision-making should explicitly incorporate expected benefits and limitations, comorbidities, concomitant drugs, and patient preference. [7]

Use a treat-to-target strategy with serum urate below 6 mg/dL. Sustained urate reduction is intended to dissolve MSU crystals, suppress flares, and resolve tophi; allopurinol is the first-line ULT and should begin at a low dose with gradual escalation. [10][7][14]

Monitor serum urate and renal function repeatedly during dose titration and maintenance. A fixed allopurinol dose of 300 mg daily is often insufficient to achieve target serum urate, so a subtarget result should trigger adherence assessment and dose-adjustment planning rather than acceptance of persistent hyperuricemia. [7]
- Do not frame lifestyle changes as a substitute for ULT when ULT is indicated; encourage weight management, exercise, and reduced alcohol consumption as adjunctive measures. [7]
- A gradual febuxostat dose-escalation strategy reduced early flare risk compared with full-dose initiation in FORTUNE-1. [10]
- Current evidence supports initiating ULT during a flare in selected patients when podagra and elevated serum urate are present and infection is not suspected; this remains a clinical decision requiring reliable flare control and patient engagement. [18]

*Treat-to-target urate-lowering strategy. [7][10][14][18]*

| Decision point | Action | Monitoring or adjustment |
| --- | --- | --- |
| Recurrent attacks, tophi, urate arthropathy, renal damage, or symptomatic very high serum urate | Discuss and initiate ULT when aligned with patient priorities. [7] | Review comorbidities and concomitant medications during treatment selection. [7] |
| Starting allopurinol | Start at a low dose and escalate gradually. [10] | Measure serum urate and renal function; increase therapy as needed to reach urate below 6 mg/dL. [7][14] |
| Serum urate remains at or above 6 mg/dL | Do not assume allopurinol 300 mg daily is adequate. [7] | Assess adherence and continue dose-adjustment strategy with renal-function monitoring. [7] |
| Initiation during active flare | May be considered when clinical gout is convincing and infection is not suspected. [18] | Pair with effective anti-inflammatory flare management and prophylaxis planning. [12][18] |

## Prevent mobilization flares when initiating urate lowering

Early flares from deposit dissolution commonly undermine persistence with urate-lowering therapy.

Initiate anti-inflammatory prophylaxis when starting ULT because crystal deposit dissolution increases acute flare frequency during the early phase and can reduce adherence. High-quality evidence supports low-dose colchicine or low-dose NSAID prophylaxis in patients initiating ULT. [22][12]

Use low-dose colchicine 0.5 mg once or twice daily or naproxen 250 mg orally twice daily as described first-line prophylaxis options, for up to 6 months. If these are contraindicated, not tolerated, or ineffective, low-dose prednisone or prednisolone may be considered; longer glucocorticoid exposure requires particular caution because cumulative toxicity can outweigh prophylactic benefit. [22][11]

In CKD, individualize prophylaxis rather than automatically using standard regimens. EULAR recommends colchicine dose reduction for prophylaxis during the first 6 months of ULT, while long-term colchicine exposure has been associated with bone marrow suppression and neuromyotoxicity in the general population. [5][11]
- Use prophylaxis for months rather than days: drugs used for flare prevention are generally lower dose and longer duration than flare-treatment regimens. [11]
- Recheck interacting medications throughout prophylaxis because colchicine disposition is affected by CYP3A4 and P-glycoprotein pathways. [5][24]
- Do not use IL-1 blockers as routine prophylaxis; canakinumab and rilonacept have shown prophylactic efficacy, but IL-1 blockers are not approved for this purpose. [22]

*Prophylaxis options during initiation of urate-lowering therapy. [5][11][12][22][24]*

| Regimen | Duration described | Selection issue |
| --- | --- | --- |
| Colchicine 0.5 mg once or twice daily | Up to 6 months. [22] | Reduce for prophylaxis in severe CKD settings per EULAR; review renal/hepatic function and P-glycoprotein/CYP3A4 interactions. [5][24] |
| Naproxen 250 mg orally twice daily | Up to 6 months. [22] | Use only when NSAID risks are acceptable; CKD may preclude use. [5] |
| Low-dose prednisone or prednisolone | Alternative when first-line prophylaxis is contraindicated, not tolerated, or ineffective. [22] | Limit exposure when possible because prolonged glucocorticoid therapy has important toxicity tradeoffs. [11] |

## Escalate uncontrolled tophaceous gout to pegloticase-based care

Use intravenous uricase therapy for persistent disease not controlled with conventional urate lowering.

Consider pegloticase in patients with uncontrolled gout who have baseline serum urate at least 7 mg/dL and inability to maintain urate below 6 mg/dL on other ULT, intolerable adverse effects with current ULT, and/or clinically evident tophaceous deposits. In clinical trials, sustained urate below 6 mg/dL for more than 300 hours was observed with 8 mg and 12 mg doses in a dose-ranging study. [1]

For pegloticase therapy, assess clinical response using sustained serum urate control and tophus burden. In the labeled trial population, a month-6 responder maintained serum urate below 6 mg/dL for at least 80% of month 6; methotrexate coadministration produced a higher proportion of month-6 and month-12 responders than pegloticase alone. [1]

Plan infusion prophylaxis and flare prophylaxis before treatment. Trial participants received an oral antihistamine, intravenous corticosteroid, and acetaminophen for infusions, plus NSAID and/or colchicine flare prophylaxis beginning at least 1 week before therapy. [1]
- Use persistent serum urate above target on optimized conventional therapy, ULT intolerance, or clinically evident tophi to prompt reassessment for pegloticase eligibility. [1]
- Monitor serum urate longitudinally because sustained biochemical response is central to pegloticase efficacy assessment. [1]

*Pegloticase escalation framework for uncontrolled gout. [1]*

| Clinical feature | Implication | Action |
| --- | --- | --- |
| Serum urate at least 7 mg/dL with failure to maintain below 6 mg/dL on other ULT | Meets a labeling-type uncontrolled-gout entry feature. [1] | Consider pegloticase evaluation after confirming persistent treatment failure or intolerance. [1] |
| Clinically evident tophi | Reflects high crystal burden and was present in 71% of trial participants. [1] | Track tophus burden alongside serum urate response. [1] |
| Pegloticase infusion planned | Infusion and flare prophylaxis were used in clinical trials. [1] | Use oral antihistamine, intravenous corticosteroid, acetaminophen, and NSAID and/or colchicine prophylaxis as trial-based preparation. [1] |

## References
1. KRYSTEXXA — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=6e566303-d93a-4130-b764-25749829aa95&type=pdf
2. 2015 Gout classification criteria: an American College of ... — ard.bmj.com — https://ard.bmj.com/content/annrheumdis/74/10/1789.full.pdf
3. Dual-energy CT for the diagnosis of gout: an accuracy and ... — ard.bmj.com — https://ard.bmj.com/content/74/6/1072
4. Abstract — ard.bmj.com — https://ard.bmj.com/content/82/Suppl_1/257.1
5. Safety and efficacy of colchicine in crystal-induced arthritis ... — rmdopen.bmj.com — https://rmdopen.bmj.com/content/10/1/e003872
6. Open-label randomised pragmatic trial (CONTACT ... — ard.bmj.com — https://ard.bmj.com/content/79/2/276
7. Latest guidance on the management of gout — www.bmj.com — https://www.bmj.com/content/362/bmj.k2893
8. Management of Gout: A Systematic Review in Support ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M16-0461
9. Gout | Annals of Internal Medicine — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/ANNALS-24-03951
10. Gout | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-019-0115-y
11. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology — www.nature.com — https://www.nature.com/articles/s41584-021-00657-4
12. Management of Acute and Recurrent Gout: A Clinical ... — annals.org — https://annals.org/aim/fullarticle/2578528/management-acute-recurrent-gout-clinical-practice-guideline-from-american-college
13. How Would You Manage This Patient With Gout? — annals.org — https://annals.org/aim/fullarticle/2717144/how-would-you-manage-patient-gout-grand-rounds-discussion-from
14. Gout Flare Burden in the United States: A Multiyear Cross ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.11759
15. Treatment advances in gout — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521694221000619
16. 2024 Update of Chinese Guidelines for Diagnosis and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1756-185x.70375
17. Gout and its management - Dalbeth - 2024 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/imj.16382
18. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0049017224000088
19. Comparative Risk of Gout Flares When Initiating or Escalating ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25309
20. Gout in Primary Care: Clinical Overview and Case Study — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1555415526001492
21. Single source dual-energy computed tomography in the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0720048X16302431
22. Prophylaxis for acute gout flares after initiation of urate ... — academic.oup.com — https://academic.oup.com/rheumatology/article/53/11/1920/1792549
23. 2020 American College of Rheumatology Guideline for the ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24180?e-page-19fe3cd=2&e-page-5234398=2&e-page-85855cf=4&term=p%C3%B3s-gradua%C3%A7%C3%A3o
24. Role of Interleukin‐1 Inhibitors in the Management of Gout — accpjournals.onlinelibrary.wiley.com — https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.1265

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.